FDA Panel to Review Genentech, Inc.'s (Jobs) Avastin for Breast Cancer

LOS ANGELES, Sept 13 (Reuters) - Genentech Inc.'s blockbuster drug Avastin will be reviewed as a first-line treatment for metastatic breast cancer by a U.S. Food and Drug Administration advisory panel in December, the company said on Thursday.